Skip to main content
. 2021 Jan 12;35(5):398–409. doi: 10.1038/s41371-020-00477-1

Fig. 10. Prescribing behavior after the Valsartan recall in Canada.

Fig. 10

Most patients (74%) were switched to a different ARB (not 357 valsartan). No alternative antihypertensive drug was prescribed in 11% of the patients [24].